- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02378779
Consultations Reason for Genital, Urinary or Psychological Humans in General Practice (GETUP)
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ambert, France, 63600
- Cabinet Medical
-
Assas, France, 34820
- Cabinet médical - 89 Bis Rue de la Calade
-
Augerolles, France, 63930
- Cabinet Medical
-
Avermes, France, 0300
- Cabinet Medical
-
Bellerive-sur-Allier, France, 03700
- Cabinet médical - Esplanade Mitterrand 5
-
Brest, France, 29200
- Cabinet de médecine générale
-
Brest, France, 29200
- Cabinet du 122 rue Paul Masson
-
Brest, France, 29200
- Cabinet médical Place J. London
-
Clarensac, France, 30870
- Cabinet Medical
-
Fleury, France, 11560
- Cabinet Medical
-
Lanmeur, France, 29620
- Pôle universitaire de Lanmeur
-
Le Mayet de Montagne, France, 03250
- Cabinet Medical
-
Le Puy En Velay, France, 43000
- Cabinet Medical
-
Lempdes sur Allagnon, France, 43410
- Cabinet Medical
-
Narbonne, France, 11000
- Cabinet médical du 38 Bd 1848
-
Ondres, France, 40440
- Cabinet de médecine générale
-
Pont de Buis Les Quimerch, France
- Cabinet de médecine générale
-
Restinclières, France, 34160
- Cabinet médical du 5 Descente des Oliviers
-
Saint Nicolas du Pelem, France, 22480
- Cabinet Medical
-
Saint Vincent de Tyrosse, France, 40230
- Groupe médical Tourren
-
Saubrigues, France, 40230
- Cabinet de médecine générale
-
Thézan Les Béziers, France, 34490
- Cabinet Medical
-
Trégunc, France, 29910
- Cabinet médical - 39 rue Saint Philibert
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male patients overbetween 18 and 80 years old and
- Patients consulting for a sexual, urogenital or psychological reason according to Interntational Classification of Primary Care (ICPC-2) will be included.
Exclusion Criteria:
- Patients consulting for Aanother reason for visiting thethan urogenital pattern, sexual or psychological
- Nonunderstanding of the French language
- Patients with psychiatric disorders affecting judgement
- Patient refusal to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Interventional GP : GP trainned in communication skills
The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life. He must so answer to the questionary PEDT. Then the interventional GP group must use one of the six strategies to approach the subject of premature ejaculation. There three strategies of attitude (Total attention, Humour, Take the drama out) and three investigative strategies (Question about premature ejaculation, Symptoms of premature ejaculation, Help to verbalize). |
The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).
Total attention of the GP to approach the subject of premature ejaculation during all the consultation
Use the humour to approach the subject of premature ejaculation
Take the drama out to approach the subject of premature ejaculation
Question about premature ejaculation during the GP consultation
GP's observation about signs of premature ejaculation
Help for the patient to speak about premature ejaculation
|
|
Other: Usual care : GP did not trainnd in communication skills
The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life. He must so answer to the questionary PEDT. This classical GP group make a classical consultation like each day without use any strategies to speak about |
The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The impact of training general practitioners in communication skills
Time Frame: Day 0 - 4 weeks
|
The impact of training general practitioners in communication skills on the rate of patients bringing up the topic of premature ejaculation with their GP.
To measure the proportions of patients bringing up the topic of premature ejaculation with their GP, the GPs in the two groups were asked to fill in a questionnaire after the consultation on whether the topics tackled were genital, urinary or psychological.
The aim of detailing the different topics broached was to avoid contamination bias in the control group.
|
Day 0 - 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of quality of life
Time Frame: Day 0 - 4 weeks
|
The quality of life will be evaluated with the SF-12 health assessment scale.
The SF-12 was designed to measure general health status from the patient's point of view.
The SF-12 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health.
|
Day 0 - 4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marie BARAIS, GP, GP department, ERCR SPURBO
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GETUP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premature Ejaculation
-
BioprojetRecruitingPremature (Early) EjaculationFrance
-
Janssen Research & Development, LLCCompletedSexual Dysfunction, Physiological | EjaculationGermany, Spain, Portugal, Finland, Sweden, Austria
-
Tanta UniversityRecruitingPremature Ejaculation | Male Sexual Dysfunction | Lifelong Premature EjaculationEgypt
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedSexual Dysfunction | Ejaculation
-
Al Mouwasat HospitalCompletedPremature (Early) EjaculationSaudi Arabia
-
Sohag UniversityCompletedVitamin D, Vitamin B12 and Folic Acid Among Patients With Premature EjaculationEgypt
-
Abant Izzet Baysal UniversityCompletedEjaculatory Dysfunction | Sexual Dysfunction Male | Premature (Early) EjaculationTurkey (Türkiye)
-
Başakşehir Çam & Sakura City HospitalNot yet recruitingPremature Ejaculation | EjaculationTurkey (Türkiye)
-
PfizerCompletedEjaculationUnited States, Australia, Canada, United Kingdom
-
PfizerCompletedEjaculationItaly, Spain, Australia, Austria, Canada, Czech Republic, France, Germany, Israel, Norway, Poland, Sweden, Turkey, Netherlands